Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for refractory dermatomyositis-associated rash (ACDM)
jRCTs031200005Phase 1Completed
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apremilast in dermatomyositis (DM). Primary endpoint: Safety. Started Apr 2020; status: completed.
02
Drugs
apremilast
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on jRCTs031200005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200005.